Insights & Resources

Clinical evidence, reimbursement guidance, and practice development insights from the wound care frontline

We write about the things that actually matter to wound care practices — billing changes that affect your bottom line, clinical evidence you can act on, and practical strategies for building a wound care program that delivers results for patients and your practice alike.

February 28, 2026 Patient Safety

Dermabond Allergy? Here Are Safer, More Effective Alternatives for Wound Closure

Up to 17% of patients develop allergic contact dermatitis to Dermabond's cyanoacrylate adhesive. Discover how biologic alternatives like fish skin grafts and spider silk offer safer, clinically superior wound closure without the allergy risk.

Read Article
February 25, 2026 Practice Development

Building a Wound Care Program in Your Practice: From First Patient to Full Caseload

A step-by-step guide to launching an advanced wound care program — from assessing your patient base and building a formulary to training your billing team and marketing to referral sources. Realistic revenue expectations included.

Read Article
February 22, 2026 Billing & Coding

Coding and Billing for Advanced Wound Care Biologics in 2026: A Practice Manager's Playbook

The complete guide to billing under the new CMS framework — CPT application codes, Q-code product reporting, FDA/HCPCS alignment requirements, documentation checklists, and strategies for avoiding the most common denial triggers.

Read Article
February 19, 2026 Clinical Practice

Wound Bed Preparation Before Biologic Application: Getting It Right the First Time

The TIME/TIMERS framework applied to biologic graft preparation — debridement strategies, infection management, moisture balance, and a practical readiness checklist so you never waste product on an unprepared wound bed.

Read Article
February 17, 2026 Evidence Review

Fish Skin vs. Traditional Skin Substitutes: What the Clinical Evidence Actually Shows

An honest, evidence-based comparison of fish skin grafts against the full spectrum of skin substitutes — human-derived, synthetic, and xenograft. Includes detailed Odinn Trial results and meta-analysis data with clinical context.

Read Article
February 14, 2026 Regulatory

The 2026 CMS Skin Substitute Reclassification: What It Means for Your Wound Care Practice

CMS reclassified skin substitutes from biologics to "incident-to" supplies with a flat $127/cm² rate. Here's what changed, which products are affected, and a 6-step compliance checklist for your practice.

Read Article